Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues

Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues

We are witnessing a paradigm shift in drug development and clinical practice to fight the novel coronavirus disease (COVID-19), and a number of clinical trials have been or are being testing various pharmacological approaches to counteract viral load and its complications such as cytokine storm. How...

Full description

Bibliographic Details
Main Authors: Milo Gatti, Eleonora Turrini, Emanuel Raschi, Piero Sestili, Carmela Fimognari
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Pharmaceuticals
Subjects:
coronavirus disease (COVID)-19
janus kinase (JAK) inhibitors
baricitinib
ruxolitinib
real word evidence
adverse effects
Online Access:https://www.mdpi.com/1424-8247/14/8/738

Internet

https://www.mdpi.com/1424-8247/14/8/738

Similar Items